The present invention relates to a biomarker for diagnosing pancreatic cancer and use thereof. The marker according to the present application can significantly predict or determine, through a 14-multimarker panel, the onset likelihood, early diagnosis, and severity of pancreatic cancer or precancerous lesions of pancreatic cancer, and can be used in research on the tumorigenesis of pancreatic cancer.

Methods for determining an in vitro release profile of peanut allergens in a sample are provided. Methods for determining one or more signatures of peanut allergens in a sample are provided.

Method and devices are provided for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis. In certain aspects, devices of the embodiments allow for the collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis.

The present disclosure relates to a method of characterizing proteins in a sample. The method includes: removing non-ionic surfactant from the sample via denaturing size-exclusion chromatography to form a denatured sample; eluting the denatured sample via liquid chromatography to collect fractions of the sample, wherein the fractions of the sample include a protein fraction; lyophilizing the protein fraction to increase protein concentration; reconstituting the lyophilized protein fraction with a buffer comprising a surfactant to denature the protein; digesting the denatured protein fraction with an enzyme; and analyzing the digested protein fraction.

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population.

The present disclosure relates to CO.sub.2-based chromatography for the efficient and precise separation of Vitamin D metabolites.

A method for detecting a list of known biopolymer molecules comprises: calculating, for each biopolymer, a respective list of oligomer molecules predicted to be produced by chemical processing; calculating, for each oligomer molecule, a respective predicted chromatographic elution time period; assigning, for each biopolymer molecule, one or more selected oligomer molecules to be detected, wherein the selecting is performed using weighted selection probabilities determined from the predicted elution times; scheduling a plurality of oligomer detection events of a detection system, wherein each oligomer detection event corresponds to a respective one of the predicted elution time periods; performing the chemical reaction or processing of the sample to generate a processed sample; introducing the processed sample into a chromatographic system; introducing any eluting oligomers into the detection system; and operating the detection system so as to search for each of the selected oligomer molecules in accordance with the scheduled detection events.

The present application relates to methods for determining the concentration of one or more hormones in a sample by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or bio transformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.

The present application discloses stability-indicating potency assays for influenza vaccines.